In the news
Building a Psychedelic Enterprise
Video of an event hosted by UCL Society for the Application of Psychedelics and LSESE Neuroscience Society. COMPASS founders talk about patients, profits, patents and psychedelics
Psychedelic Times: Interview with Rick Doblin, founder and executive director, MAPS
Psychedelic Times interviews Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), about psychedelics and capitalism.
Psilocybin Could Be Legal for Therapy by 2021
"For the first time in U.S. history, a psychedelic drug is on the fast track to getting approved for treating depression by the federal government", Rolling Stone
FDA “Breakthrough” Ruling on Magic Mushrooms, Explained by Scientists
“This is an important advance in bringing these compounds out of the dark ages”. Inverse explains the recent FDA Breakthrough obtained by COMPASS and what this means.
Company of the Month: COMPASS Pathways
MedCity names COMPASS as their Company of the Month.
Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA
Article from New Atlas covering COMPASS’s breakthrough designation, awarded by the FDA, and other psychedelic research.
The renaissance of psilocybin as a viable treatment option
Article from pharmaceutical-technology.com listing current clinical trials involving psilocybin.
FDA Approves Psychedelic Magic Mushrooms
The Food and Drug Administration has approved the use of the psychedelic ingredient in magic mushrooms for a drug trial for treatment-resistant depression.
Q&A: Compass Pathways’ Goldsmith on fighting depression with psilocybin
The British startup is about to begin the largest clinical trial ever to test whether psilocybin can be used to treat depression
‘Reluctant Psychonaut’ Michael Pollan Embraces The ‘New Science’ Of Psychedelics
National Public Radio Fresh Air podcast with Michael Pollan on his new book “How to change your mind”.
Depression – The Psychedelic Cure?
Rob Reid interviews COMPASS founders Katya Malievskaia and George Goldsmith for his After On podcast. They discuss the motivations behind COMPASS as well as the clinical history of psychedelics.
My Adventures With The Trip Doctors
The researchers and renegades are bringing psychedelic drugs into the mental health mainstream. Read more about this feature article in the New York Times by Michael Pollan on psychedelic therapy.
Might LSD Be Good For You?
Many psychedelic drugs are non-addictive, and can be helpful in treating all sorts of psychological conditions, argues Michael Pollan. Sam Leith discusses and reviews “How to Change Your Mind: The New Science of Psychedelics” by Michael Pollan.
Magic Mushrooms May Treat Depression
A trial will assess whether psilocybin, the active ingredient in magic mushrooms, can help. This article is from The Sunday Times about COMPASS Pathways’ trial for treatment-resistant depression
Mushroom Emerge From Underground
“Magic mushrooms show promise to treat depression and anxiety–and major academic institutions and Silicon Valley are stepping up research and investment. The wellness travel space, in very creative ways, is moving from experiential to truly emotional and transformative travel.”
Peter Thiel’s Bet on Magic Mushrooms
“High-profile Silicon Valley investor Peter Thiel made a bet last year on a company with an unusual idea for treating depression: psychedelics.”
Mind Menders: How Psychedelic Drugs Rebuild Broken Brains
The healing powers of illegal drugs like MDMA and psilocybin are finally living up to the hype – and they are already transforming our view of mental illness.
‘Magic Mushrooms’ Take a Trip Into Clinical Trials
Hundreds of Europeans with depression will soon have the chance to turn on, tune in and drop out of existing drug treatments, in the largest clinical trial ever launched to assess the medicinal effects of a psychoactive substance.
Can Magic Mushrooms Provide Lasting Peace?
Psilocybin has been illegal in the United States for more than 40 years. But Mr. Mihai, who had just finished treatment for Stage 3 Hodgkin’s lymphoma, was participating in a study looking at whether the drug can reduce anxiety and depression in cancer patients.
Just One Dose of This Psychedelic Drug Can Ease Anxiety
In two new studies released simultaneously by researchers at New York University and Johns Hopkins, doctors reveal that a single dose of psilocybin—a compound from magic mushrooms—can ease anxiety and depression for up to six months.
Magic Mushroom Drug Helps People With Cancer Face Death
Can a psychedelic trip change the way people with life-threatening cancer face death? Results from two clinical trials suggest so, as reported in New Scientist.
‘Magic Mushroom’ Drug Lifts Depression In First Human Trial
An Imperial College London proof of concept study on psilocybin for treatment resistant depression has interesting results. The hallucinogenic drug derived from magic mushrooms could be useful in treating depression, the first safety study of this approach has concluded.
How Magic Mushrooms Could Treat Depression
Treating depression is a major challenge, since among the millions of people affected worldwide, only one in five tends to respond well to antidepressants. Now, there’s a new, albeit controversial, approach being considered by scientists.
One Writer’s Trip
A video of journalist Michael Pollan’s autobiographical talk on the altered states of consciousness that certain plants and fungi allow us to achieve.
Real Trip Treatment
Research into psychedelics, shut down for decades, is now yielding exciting results. In this article from The New Yorker, Michael Pollan presents a considered overview of psychedelic-assisted therapy, its history and its potential benefit to patients.
‘Magic Mushrooms’ and The Healing Trip
The way in which we commonly perceive so-called magic mushrooms—as the means to youthful psychedelic adventure—is undergoing a radical transformation.
Can Mushrooms Treat Depression?
"The brains on psilocybin showed radically different connectivity patterns between cortical regions (the parts thought to play an important role in consciousness). "
Hallucinogens Have Doctors Tuning In Again
Scientists are taking a new look at hallucinogens, which became taboo among regulators after enthusiasts like Timothy Leary promoted them in the 1960s with the slogan “Turn on, tune in, drop out.”